At what enterprise value was COSMOGEN acquired in 2014?

You can find the full valuation details of COSMOGEN on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Industry & Manufacturing industry currently tracks an average EBITDA multiple of 11.1x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of COSMOGEN when it was acquired by MBO+?

The exact EV/EBITDA multiple for COSMOGEN is available on mynth capital. For comparison, the Industry & Manufacturing sector currently shows an average EBITDA multiple of 11.1x. Join our community for free to access full valuation data and industry trends.

When was COSMOGEN acquired by MBO+?

COSMOGEN was acquired by MBO+ in 2014.

What was the revenue of COSMOGEN at the time of the deal?

The revenue of COSMOGEN at the time of the deal is estimated to be in the range of 10M - 30M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of COSMOGEN during the acquisition?

COSMOGEN's EBITDA is estimated to be in the range of 0M - 5M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the COSMOGEN acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the COSMOGEN deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.fusacq.com/buzz/mbo-partenaires-investit-dans-l-expert-en-cosmetiques-alkos-cosmogen-a74790_fr_

← DATABASE

Home Database Industry & ManufacturingCOSMOGEN

04/2014

COSMOGEN

Acquired by

MBO+

FRANCE Chemicals & Materials / Packaging & Containers REV 10M - 30M EUR

COSMOGEN acquired by MBO+

FRANCE Chemicals & Materials / Packaging & Containers REV 10M - 30M EUR

Context

The Management Buy Out operation led by MBO Partenaires allows Dominique Vautier to become the manager and shareholder of the Alkos-Cosmogen group, while Gérard Gieux retains a significant stake in the capital and a strong involvement in the Group's strategy. The key executives become shareholders and will support Dominique Vautier in the implementation of an ambitious strategic plan, based on organic growth, the development of new products, and international development.

COSMOGEN, which reported an EBITDA margin of LOGIN in 2015, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Industry & Manufacturing sector (11.1x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Industry & Manufacturing market trends

Target

Cosmogen is a French company specializing in the design and provision of primary packaging and application solutions for the global cosmetics sector. Following its spin-off from Alkos Group in 2016, the firm has concentrated on creating technical and often patented products, including innovative applicators, brushes, and accessories for skincare and makeup. Cosmogen's primary client base is located in Europe and includes major international brands such as L'Oréal, Dior, Caudalie, and Clarins. The company utilizes a "fabless" business model, which allows it to focus on its core competencies of research, development, and design while maintaining a flexible and scalable supply chain. Cosmogen demonstrates a strong commitment to corporate social responsibility; it became a mission-driven company ("entreprise à mission") in 2022, legally embedding social and environmental objectives into its corporate framework. In late 2025, its efforts in sustainability were acknowledged with an EcoVadis Gold medal for its ESG performance.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2015

2014

Other operations with COSMOGEN

Date	Acquirer	Target	Country	Sector	Deal Context
05/2026	COSMOGEN	ASQUAN	CHINA	Chemicals & Materials	This transaction represents Cosmogen's first external growth initiative since its spin-off and is a transformative step to double its operational scale. Driven by its controlling shareholder, Weinberg Capital Partners, the acquisition aims to create a new global reference in the premium beauty packaging market, the Cosmogen & Asquan Group. The strategic rationale is founded on the strong complementarities between the two entities. Cosmogen contributes its deep expertise in patented, technical applicators and its established relationships with major European beauty conglomerates. Asquan provides a broad, multi-category product portfolio, a significant foothold in the dynamic U.S. market through its work with independent brands, and well-regarded operational processes. This merger creates a more resilient and diversified group with an expanded product catalog, a balanced geographic footprint, and a wider client portfolio. The deal is a direct response to the consolidation trend within the wider cosmetics industry, giving the combined entity the critical size required to serve global brands more effectively and enhance its competitive positioning. The integration process is reinforced by the founder of Asquan joining the new group's leadership as Chief Operating Officer.
12/2024	WEINBERG CAPITAL PARTNERS / BNP PARIBAS DEVELOPPEMENT	COSMOGEN	FRANCE	Chemicals & Materials	Weinberg Capital Partners has arranged to acquire a majority shareholding in Cosmogen, a leading developer of innovative application solutions for the cosmetics industry. The investment, which is the third from its WCP#4 LBO fund, was made in partnership with its co-investment vehicle, WCP Co-Invest, and with co-investor BNP Paribas Développement. This transaction marks the exit of the former majority shareholder, MBO+, which had supported Cosmogen's growth over an eight-year period. The acquisition was structured as a leveraged buyout (LBO) and was deemed a strategic fit for Weinberg Capital Partners' investment criteria. The firm was attracted to Cosmogen's B2B services model, its position in a sector where Weinberg has deep expertise, its mature environmental, social, and governance (ESG) framework, and its strong focus on client satisfaction. Under the new ownership, Cosmogen is expected to accelerate its development and pursue a consolidation strategy within its sector, both domestically in France and on an international scale. Weinberg Capital Partners plans to leverage its extensive experience in executing add-on acquisitions to support Cosmogen's management team, led by CEO Priscille Allais, in achieving this next phase of expansion and solidifying its market leadership.

REFERENCES

Revenue range: 10M - 30M EUR

EBITDA range: 0M - 5M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of COSMOGEN by MBO+ are reserved for mynth community members. Register for free to unlock full data.

Authors: mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: cosmogen

Acquirer: mbo+